FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新銳醫藥國際控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06108 | 說明 | 新銳醫藥 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | 0.01 | HKD | | 150,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 15,000,000,000 | HKD | 0.01 | HKD | | 150,000, ...

Group 1 - The core point of the article is that New Horizon Health (06108) has completed a share placement agreement, with a total of 33.432 million shares being placed at a price of HKD 0.225 per share, raising approximately HKD 7.4 million in net proceeds [1] - The shares placed represent about 16.66% of the company's issued share capital as of the announcement date [1] - The stock value deposited by shareholders at Changli Securities is HKD 8.2243 million, accounting for 20% of the total [1]

Group 1 - The core viewpoint of the article highlights that New Horizon Health (06108) has completed a share placement agreement, with a total of 33.432 million shares being placed at a price of HKD 0.225 per share, representing approximately 16.66% of the company's issued share capital post-completion [1] - The placement is expected to generate a net proceeds of approximately HKD 7.4 million for the company [1] - As of December 23, the stock valued at HKD 8.2243 million was deposited with Changli Securities, accounting for 20% of the total stock held by shareholders [1]

Group 1 - The company, New Horizon Health (06108), announced that the conditions of the placement agreement have been fulfilled and will be completed on December 23, 2025, according to the terms and conditions of the placement agreement [1] - A total of 33.432 million shares will be placed, representing approximately 16.66% of the company's issued share capital immediately after completion of the placement [1] - The placement shares were sold at a price of HKD 0.225 per share, with the net proceeds from the placement amounting to approximately HKD 7.4 million [1]

Group 1 - The core point of the article is that New Wave Pharmaceuticals (06108) has successfully completed the conditions of a placement agreement, with the placement of 33.432 million shares, representing approximately 16.66% of the company's issued share capital as of the announcement date [1] - The shares were placed at a price of HKD 0.225 per share, and the net proceeds from the placement amount to approximately HKD 7.4 million [1]

Group 1 - The core point of the article is that New Horizon Health (06108.HK) has successfully completed a placement agreement, raising approximately HKD 7.4 million through the issuance of 33.43 million shares at a price of HKD 0.225 per share [1] - The placement shares represent about 16.66% of the company's issued share capital immediately following the completion of the placement [1] - The placement was made to no fewer than six subscribers, indicating a diversified investor base [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 新銳醫藥國際控股有限公司 呈交日期： 2025年12月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06108 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | 已發行股份總數 | | 事件 | ...

New Ray Medicine International Holding Limited （於百慕達註冊成立之有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 任 何 證 券 之 邀 請 或 要 約。 （股份代號：6108） 完成根據一般授權配售新股份 配售代理 昌利證券有限公司 董事會欣然宣佈，配售協議所載配售事項條件已獲達成及於二零二五年十二 月 二 十 三 日 根 據 配 售 協 議 之 條 款 及 條 件 完 成。 合 共33,432,000股 配 售 股 份（佔 緊 隨 完 成 後 於 本 公 告 日 期 本 公 司 已 發 行 股 本 約 16.66%）已 按 配 售 價 每 股 配 售 股 份0.225港 元 配 售 予 ...

Core Viewpoint - The company, New Wave Pharmaceuticals (06108), has announced a placement agreement to issue up to 33.432 million shares at a price of HKD 0.225 per share, which represents a discount to the market price [1] Group 1: Placement Details - The maximum number of shares to be placed represents approximately 20.00% of the company's existing issued share capital as of the announcement date [1] - The placement price of HKD 0.225 per share reflects an 8.16% discount to the closing price of HKD 0.245 on the last trading day [1] - The placement price also shows a 10.57% discount compared to the average closing price of approximately HKD 0.2516 over the five trading days preceding the last trading day [1] Group 2: Financial Implications - The total gross proceeds from the placement are expected to be approximately HKD 7.5 million, with net proceeds estimated at around HKD 7.4 million after deducting placement fees and other expenses [1] - The net proceeds from the placement will be fully utilized for acquiring additional distribution rights related to the company's core business [1]

Core Viewpoint - The company, New Wave Pharmaceuticals (06108), has announced a placement agreement to issue up to 33.432 million shares at a price of HKD 0.225 per share, which represents a discount to the market price [1] Group 1: Placement Details - The placement will be made to at least six independent third-party investors [1] - The maximum number of shares to be placed represents approximately 20.00% of the company's existing issued share capital as of the announcement date, and about 16.66% of the enlarged issued share capital post-placement [1] - The placement price of HKD 0.225 per share reflects an 8.16% discount to the last closing price of HKD 0.245 and a 10.57% discount to the average closing price of HKD 0.2516 over the five trading days preceding the last trading day [1] Group 2: Financial Implications - The total gross proceeds from the placement are expected to be approximately HKD 7.5 million, with net proceeds estimated at around HKD 7.4 million after deducting placement fees and other expenses [1] - The net proceeds from the placement will be used entirely for acquiring additional distribution rights related to the company's core business [1]